Clinical solutions

clinical Solutions

Sysmex analysers deliver far more than just a blood count: fully backed by scientific evidence, you can now select a range of new clinical values. How do they help? For clinicians: they’ll help you with early diagnosis so that you can start targeted treatment, change or modify it faster. For labs: you’ll enjoy enhanced competitive strength and client satisfaction and loyalty.

Confident excluding malignancy?

Now you can be.
Click here

Confident with your apheresis process?

Now you can be.
Click here

Confident managing thrombocytopenias?

Now you can be.
Click here

Confident differentiating infection?

Now you can be.
click here

Opening doors to new solutions

Confident with your apheresis process?

The number of haematopoietic stem cell transplantations (HSCT) is increasing, and nowadays mobilised peripheral blood is the prime source of haematopoietic stem cells. But can your haematology analyser count stem cells in mobilised peripheral blood samples? With the XN-Series you can.

The XN Stem Cells method has been shown to be comparable with the CD34 count in mobilised peripheral blood. Use it to determine the optimal apheresis starting point and reduce the number of expensive CD34 counts. Or rapidly analyse the intermediate product during stem cell collection to monitor yield and optimise collection time. All from a routine blood test.

The result: an improved workflow for a higher turnaround of patients, better resource management and, despite the circumstances, a more positive patient experience.

For more details, check out our White Papers.

back

Confident managing thrombocytopenia?

Determining the cause of thrombocytopenia is tricky: how do you differentiate between decreased bone marrow production and increased destruction or consumption of peripheral blood? And so choose the optimal therapy? The XN-Series can help.

The immature platelet fraction (IPF) is a versatile parameter that helps determine the cause of thrombocytopenia as described above.

The IPF absolute count (IPF#) reflects the bone marrow response to immune thrombocytopenia treatment in real-time. It shows which mechanism is proving effective and helps to assess bleeding risks. This may improve patient care and reduce costs.

IPF is specific, fast and easily accessible and is ordered and processed together with the complete blood count.

Beyond that, IPF parameters can also help in other disease areas. Increased IPF# values have been linked to the risk of future cardiovascular thrombotic events and to the efficacy of antiplatelet therapy. Additionally, IPF is a marker of bone marrow activity and its increase has been demonstrated to precede bone marrow recovery after haematopoietic stem cell transplantation.

For more details, check out our White Papers.

back

Confident differentiating infection?

Whether a patient has an acute infection or is already recovering has a direct impact on treatment decisions. Can your analyser differentiate between the two? With the XN-Series you can.  

The XN-Series’ optional Extended Inflammation Parameters measure the reactivity of neutrophils and lymphocytes. So now, knowing the immune response activation, you can monitor inflammatory conditions precisely.  

The inflammation parameters support different types of immune response, such as early innate, adaptive cell-mediated and humoral immune response. Use them to manage inflammatory diseases and differentiate between inflammation and infection, as well as different pathogenic causes of infection (e.g. bacterial, viral). 

For more details, check out our White Papers.

back

Confident excluding malignancy?

How do you know whether a condition is malignant or reactive? With the XN-Series you can. 

The XN-Series is equipped with a range of measurement channels that deliver information on white blood cell functionality – specifically cells’ activation and maturity status. And so let you exclude malignant conditions with confidence. The result is streamlined diagnostic pathways with fewer time-consuming and expensive follow-up tests. And clear information in terms of defining your patient’s diagnosis.  

For more details, check out our White Papers

back

Don’t miss out. Subscribe...

There's more to come: register for our newsletter below
Subscribe to the newsletter
Thank you for subscribing, check your mails for the confirmation.
Something went wrong while sending the newsletter request. Please try again later.